In operable non-small cell lung cancer (NSCLC), molecular residual disease (MRD) detection via circulating tumor DNA (ctDNA) ...

According to a new market research report, 'Minimal Residual Disease Testing Market Size, Share, Forecast, & Trends Analysis ...

Adaptive Biotechnologies get expanded medicare coverage of clonoSEQ for assessing measurable residual disease in mantle cell lymphoma: Seattle Saturday, November 9, 2024, 15:00 Hr ...

Healthcare: Cancer is a heterogeneous and multifactorial disease. Among multiple factors, it may be caused by errors, or ...

Unaware of the leak, the children entered first and did not recognize the distinct odor of mercaptan, the additive that gives ...

November 6, 2024Personalis, Inc. misses on earnings expectations. Reported EPS is $-0.64 EPS, expectations were $-0.33. Operator: Good afternoon, everyone, and welcome to Personalis Third Quarter 2024 ...

Exact Sciences (EXAS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tycho ...

Q3 2024 Earnings Call Transcript November 6, 2024 Guardant Health, Inc. beats earnings expectations. Reported EPS is $-0.45, expectations were $-0.74. Operator: Hello, everyone, and welcome to the ...

New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of ...